Bifogade filer
New study highlights the clinical value of UBC® Rapid in detecting invasive bladder cancer
Kurs
+1,80%
Likviditet
0,06 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-02-19 | 08:00 | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-23 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2024-05-22 | - | Årsstämma |
| 2024-05-03 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-03 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-17 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2022-01-19 | - | Extra Bolagsstämma 2022 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-03 | - | Extra Bolagsstämma 2021 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-02-19 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-07 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2020-05-06 | - | Årsstämma |
| 2020-02-21 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Extra Bolagsstämma 2019 |
| 2019-11-05 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-17 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-22 | - | Bokslutskommuniké 2018 |
| 2018-11-09 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-18 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2018-06-15 | - | Årsstämma |
| 2018-04-27 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-19 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2016-05-18 | - | Årsstämma |
| 2016-05-10 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-16 | - | Bokslutskommuniké 2015 |
| 2015-11-10 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | - | Kvartalsrapport 2015-Q2 |
| 2015-06-04 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2015-06-03 | - | Årsstämma |
| 2015-05-28 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-17 | - | Bokslutskommuniké 2014 |
| 2014-11-18 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-19 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2014-05-07 | - | Årsstämma |
| 2014-05-05 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-18 | - | Bokslutskommuniké 2013 |
| 2013-11-27 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-21 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-06 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2013-05-03 | - | Årsstämma |
| 2013-04-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-19 | - | Bokslutskommuniké 2012 |
| 2012-11-20 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-21 | - | Kvartalsrapport 2012-Q2 |
| 2012-06-13 | - | X-dag ordinarie utdelning AROC 0.00 SEK |
| 2012-06-12 | - | Årsstämma |
| 2012-05-22 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-05 | - | Extra Bolagsstämma 2012 |
| 2012-02-09 | - | Bokslutskommuniké 2011 |
| 2011-10-17 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-17 | - | Kvartalsrapport 2011-Q2 |
| 2011-06-01 | - | Kvartalsrapport 2011-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
A recently published scientific study has provided further evidence to support the use of UBC® Rapid as a diagnostic and monitoring tool for bladder cancer.
This multicenter study, conducted by Ecke et al. in Germany and published in the Official Journal of the Society of Urologic Oncology, analyzed 732 urine samples. The aim was to compare the diagnostic accuracy of urinary cytology with other urine-based point-of-care tests that are commercially available. This study stands out as the first to compare all available rapid tests on a large group of bladder cancer patients and healthy controls in a single setting.
The results of the study indicated that the UBC® Rapid test effectively differentiated between patients with bladder cancer and healthy controls, based on cytokeratin concentrations. These findings further support previous research and demonstrate the high detection rates of bladder cancer cases, particularly for high-grade bladder cancer patients, using the UBC Rapid test.
In addition to its diagnostic capabilities, the study highlighted the potential clinical value of the UBC® Rapid test as a urinary biomarker for detecting high-grade non-muscle invasive bladder cancer patients. This discovery could greatly aid in the management of these particular tumors.
The link for the article is:
https://www.sciencedirect.com/science/article/abs/pii/S1078143923002259
About UBC®
UBC® is a quantitative in vitro diagnostic test for the prognosis and monitoring of patients with bladder cancer. The test specifically measures soluble fragments of cytokeratin 8 and 18 in urine samples. Elevated amounts of cytokeratin fragments are found in the urine of many individuals with bladder cancer, even in the early stages of the disease. UBC® is also available as a quantitative POC test.
About AroCell
AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com